Defining current and future theranostics: Weber and colleagues look at elements in the success of PSMA theranostics and reflect on the potential for similar advances in combined diagnostics/therapeutics in other areas nuclear medicine.
Page 669
Focus on general nuclear medicine: Iagaru offers highlights and insights on general nuclear medicine topics presented at the most recent SNMMI Annual Meeting.
Page 671
Discussions with leaders: Czernin and colleagues talk with Michael J. Morris, MD, a leading expert in genitourinary oncology, on the current status and future potential for nuclear medicine in the diagnosis and treatment of prostate cancer.
Page 678
Somatostatin-based theranostics: Imperiale and colleagues summarize advances in somatostatin receptor–targeted peptide receptor radionuclide therapy, a novel paradigm in theranostics with promise for revolutionizing diagnostic and therapeutic management of neuroendocrine tumors.
Page 682
α-Radioligand therapy: Feuerecker and colleagues review important studies evaluating α-emitting targeted therapies as potential next-generation theranostics and report on 3 promising clinical applications administered systemically.
Page 685
Amino acid PET in neurooncology: Galldiks and colleagues provide an educational overview of the added clinical value of amino acid PET in glioblastoma or brain metastases for differential diagnosis and assessment of tumor extent, treatment-related changes, and treatment response.
Page 693
ChatGPT in health care: Kleesiek and colleagues look at the widespread interest in large language model–trained artificial intelligence applications, their potential in health care, and responsibilities for expert human involvement in shaping and monitoring these technologies.
Page 701
64/67Cu-SARTATE imaging and therapy: Bailey and colleagues report on first-in-humans use of 64Cu and 67Cu as a theranostic pair in patients with meningiomas, with advantageous methodology for normal-organ dosimetry.
Page 704
FAPI PET for oncologic imaging: Hirmas and colleagues present an overview of a prospective, 3-y fibroblast-activation protein inhibitor registry study, with head-to-head comparison of tumor uptake in 68Ga-FAPI and 18F-FDG PET, as well as FAP immunohistochemistry.
Page 711
68Ga-FAPI-46 PET/MRI in breast cancer NAC: Backhaus and colleagues assess and validate the diagnostic performance of follow-up breast 68Ga-FAPI-46 PET/MRI in classifying response status of local breast cancer and lymph node metastases after completion of neoadjuvant chemotherapy.
Page 717
PET in HER2+ mEGC: Lumish and colleagues describe the utility of 89Zr-trastuzumab PET in elucidating variations in human epidermal growth factor receptor 2 expression in primary tumors and metastases in metastatic esophagogastric cancer.
Page 724
PSMA only versus PSMA/FDG for treatment eligibility: Seifert and colleagues reanalyze data from patients who underwent both 18F-FDG and PSMA PET for PSMA-targeted therapy eligibility to determine whether both studies are necessary to identify suitable candidates.
Page 731
Unspecific bone uptake in 18F-PSMA-1007 PET: Seifert and colleagues explore the frequency of unspecific bone uptake and bone metastases separately for 18F-PSMA-1007 and 68Ga-PSMA-11 in biochemical recurrence of prostate cancer.
Page 738
PSMA and GRPR PET-guided prostate biopsy: Duan and colleagues report on the potential of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Page 744
Targeted α-therapy in melanoma: Ertveldt and colleagues detail studies on the mechanisms of immune activation in a melanoma model using α-targeted radionuclide therapy with 225Ac-labeled single-domain antibodies.
Page 751
177Lu-FAP6-IP-DOTA therapy: Lindeman and colleagues evaluate the performance of a fibroblast-activation protein–targeted radioligand conjugate in 4 tumor models, with potential for optimization in clinical treatment of solid tumors.
Page 759
177Lu-PSMA STP dosimetry: Brosch-Lenz and colleagues assess differences in the time-integrated activity of single-time-point versus multiple-time-point image-based dosimetry protocols for 177Lu-PSMA-617 therapy.
Page 767
Biodistribution and dosimetry of 68Ga-CBP8: Izquierdo-Garcia and colleagues determine the biodistribution, dosimetry, and pharmacokinetics of this peptide-based, type I collagen–targeted probe in PET/MRI imaging of tissue fibrosis in healthy human subjects.
Page 775
Tumor dosimetry phantoms: Carter and colleagues create computer-generated tumor models to assess the effects of tumor shape, size, and margin contour on absorbed dose for several clinically applied therapeutic radionuclides.
Page 782
PET MFR and cancer survival: Fox and colleagues detail the prognostic capabilities of quantitative PET–derived myocardial flow reserve data for overall survival in a cohort of patients with known or suspected coronary artery disease.
Page 791
18F-NOS PET and pulmonary inflammation: Wetherill and colleagues report on an 18F-NOS PET study quantifying inducible nitric oxide synthase expression to characterize oxidative stress and inflammation in the lungs of electronic cigarette users, cigarette smokers, and controls.
Page 797
NIR-FME detection of esophageal neoplasia: Gabriëls and colleagues investigate the feasibility of an epidermal growth factor receptor–targeted tracer to improve near-infrared fluorescence molecular endoscopy detection of early-stage esophageal adenocarcinoma.
Page 803
18F-Fluoromannitol PET and bacterial infection: Simpson and colleagues describe development of this novel radiopharmaceutical with the potential to specifically identify bacteria and monitor antibiotic efficacy in vivo.
Page 809
PET in recurrent brain metastases: Schlürmann and colleagues summarize evidence from a metaanalysis on the diagnostic utility of amino acid PET in differential diagnosis of recurrent brain metastases and treatment-related changes.
Page 816
Tau PET visual reads: Soleimani-Meigooni and Rabinovici offer perspective on the evolution of visual interpretation of tau PET imaging.
Page 822
PET-measured activity of microspheres: Gnesin and colleagues report on a multicenter, multi-PET-device study comparing manufacturer-declared 90Y activity in vials with quantitative 90Y PET/CT assessment of the same vials and comment on resulting implications for selective internal radiation therapy dosimetry.
Page 825
- © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.